FRED ELIAS GHALI
- Type
- Physician · Allopathic & Osteopathic Physicians / Dermatology
- Where
- GRAPEVINE, TX
- NPI
- 1639286339
- Received
- $630,893 in 1,395 records, 2019 to 2025 ($623,953 general, $6,940 research)
- As principal investigator
- $283,822 of research payments to others in 170 records
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | General payment | 297 | $130,856 |
| 2024 | General payment | 227 | $94,279 |
| 2023 | General payment | 242 | $81,061 |
| 2023 | Research payment | 1 | $2,700 |
| 2022 | General payment | 214 | $67,942 |
| 2021 | General payment | 92 | $37,073 |
| 2021 | Research payment | 2 | $3,540 |
| 2020 | General payment | 147 | $95,872 |
| 2019 | General payment | 171 | $116,866 |
| 2019 | Research payment | 2 | $700 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 118 | $404,978 |
| Consulting Fee | 40 | $139,658 |
| Travel and Lodging | 151 | $37,669 |
| Food and Beverage | 1,072 | $28,010 |
| Honoraria | 4 | $13,400 |
| Research payment | 5 | $6,940 |
| Education | 5 | $235 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-12-23 | Incyte Corporation | $7,335 | Consulting Fee | Cash or cash equivalent | Opzelura Drug, Dermatology | 2025 | |
| 2025-12-23 | Incyte Corporation | $4,890 | Consulting Fee | Cash or cash equivalent | Opzelura Drug, Dermatology | 2025 | |
| 2025-12-19 | Regeneron Healthcare Solutions, Inc. | $13 | Travel and Lodging | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-12-15 | GENZYME CORPORATION | $31 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-12-11 | Regeneron Healthcare Solutions, Inc. | $27 | Food and Beverage | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-12-09 | Ortho Dermatologics, a division of Bausch Health US, LLC | $19 | Food and Beverage | In-kind items and services | Cabtreo Drug, Dermatology | 2025 | |
| 2025-12-04 | Incyte Corporation | $20 | Food and Beverage | Cash or cash equivalent | Opzelura Drug, Dermatology | 2025 | |
| 2025-12-04 | Incyte Corporation | $19 | Food and Beverage | Cash or cash equivalent | Opzelura Drug, Dermatology | 2025 | |
| 2025-12-03 | Incyte Corporation | $811 | Travel and Lodging | Cash or cash equivalent | Opzelura Drug, Dermatology | 2025 | |
| 2025-12-03 | Incyte Corporation | $438 | Travel and Lodging | Cash or cash equivalent | Opzelura Drug, Dermatology | 2025 | |
| 2025-12-03 | Incyte Corporation | $61 | Travel and Lodging | Cash or cash equivalent | Opzelura Drug, Dermatology | 2025 | |
| 2025-12-03 | ABBVIE INC. | $29 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-12-01 | Organon Llc | $23 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-11-28 | Organon Llc | $254 | Travel and Lodging | In-kind items and services | VTAMA Drug, Dermatology | 2025 | |
| 2025-11-25 | GENZYME CORPORATION | $29 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-11-24 | Arcutis Biotherapeutics, Inc. | $23 | Food and Beverage | In-kind items and services | Zoryve Drug, Dermatology | 2025 | |
| 2025-11-21 | GENZYME CORPORATION | $5,551 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | DUPIXENT Biological, Immunology | 2025 | |
| 2025-11-21 | Regeneron Healthcare Solutions, Inc. | $4,697 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-11-21 | GENZYME CORPORATION | $42 | Travel and Lodging | Cash or cash equivalent | DUPIXENT Biological, Immunology | 2025 | |
| 2025-11-20 | Regeneron Healthcare Solutions, Inc. | $15 | Food and Beverage | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-11-19 | Incyte Corporation | $19 | Food and Beverage | Cash or cash equivalent | OPZELURA Drug, Dermatology | 2025 | |
| 2025-11-18 | Regeneron Healthcare Solutions, Inc. | $28 | Food and Beverage | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-11-18 | MAYNE PHARMA COMMERCIAL LLC | $1 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-11-17 | MAYNE PHARMA COMMERCIAL LLC | $7 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-11-17 | Arcutis Biotherapeutics, Inc. | $3 | Food and Beverage | In-kind items and services | Zoryve Drug, Dermatology | 2025 | |
| 2025-11-13 | PFIZER INC. | $20 | Food and Beverage | In-kind items and services | CIBINQO Drug, Inflammation & Immunology | 2025 | |
| 2025-11-12 | Regeneron Healthcare Solutions, Inc. | $29 | Food and Beverage | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-11-12 | LNHC, Inc | $18 | Food and Beverage | In-kind items and services | ZELSUVMI Drug, DERMATOLOGY | 2025 | |
| 2025-11-12 | Arcutis Biotherapeutics, Inc. | $17 | Food and Beverage | In-kind items and services | Zoryve Drug, Dermatology | 2025 | |
| 2025-11-08 | Galderma Laboratories, L.P. | $6 | Food and Beverage | In-kind items and services | NEMLUVIO Drug, DERMATITIS | 2025 | |
| 2025-11-06 | Incyte Corporation | $22 | Food and Beverage | Cash or cash equivalent | OPZELURA Drug, Dermatology | 2025 | |
| 2025-11-04 | Incyte Corporation | $7,312 | Consulting Fee | Cash or cash equivalent | OPZELURA Drug, Dermatology | 2025 | |
| 2025-11-04 | Incyte Corporation | $247 | Consulting Fee | Cash or cash equivalent | OPZELURA Drug, Dermatology | 2025 | |
| 2025-11-04 | PFIZER INC. | $17 | Food and Beverage | In-kind items and services | CIBINQO Drug, Inflammation & Immunology | 2025 | |
| 2025-11-03 | Arcutis Biotherapeutics, Inc. | $18 | Food and Beverage | In-kind items and services | Zoryve Drug, Dermatology | 2025 | |
| 2025-10-30 | Regeneron Healthcare Solutions, Inc. | $34 | Food and Beverage | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-10-30 | Ortho Dermatologics, a division of Bausch Health US, LLC | $21 | Food and Beverage | In-kind items and services | Cabtreo Drug, Dermatology | 2025 | |
| 2025-10-30 | Ortho Dermatologics, a division of Bausch Health US, LLC | $17 | Food and Beverage | In-kind items and services | Cabtreo Drug, Dermatology | 2025 | |
| 2025-10-28 | ABBVIE INC. | $24 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-10-24 | Regeneron Healthcare Solutions, Inc. | $2,135 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-10-24 | Incyte Corporation | $21 | Food and Beverage | Cash or cash equivalent | OPZELURA Drug, Dermatology | 2025 | |
| 2025-10-24 | Janssen Scientific Affairs, LLC | $20 | Food and Beverage | In-kind items and services | TREMFYA Drug, Immunology | 2025 | |
| 2025-10-23 | Galderma Laboratories, L.P. | $13 | Food and Beverage | In-kind items and services | NEMLUVIO Drug, DERMATITIS | 2025 | |
| 2025-10-21 | ABBVIE INC. | $11 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-10-21 | MAYNE PHARMA COMMERCIAL LLC | $1 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-10-20 | GENZYME CORPORATION | $29 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-10-20 | MAYNE PHARMA COMMERCIAL LLC | $6 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-10-17 | Regeneron Healthcare Solutions, Inc. | $34 | Travel and Lodging | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-10-16 | Arcutis Biotherapeutics, Inc. | $19 | Food and Beverage | In-kind items and services | Zoryve Drug, Dermatology | 2025 | |
| 2025-10-14 | Regeneron Healthcare Solutions, Inc. | $37 | Food and Beverage | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-10-14 | MAYNE PHARMA COMMERCIAL LLC | $1 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-10-13 | MAYNE PHARMA COMMERCIAL LLC | $7 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-10-10 | Organon Llc | $58 | Food and Beverage | In-kind items and services | VTAMA Drug, Dermatology | 2025 | |
| 2025-10-10 | Organon Llc | $40 | Food and Beverage | In-kind items and services | VTAMA Drug, Dermatology | 2025 | |
| 2025-10-10 | Organon Llc | $15 | Food and Beverage | In-kind items and services | VTAMA Drug, Dermatology | 2025 | |
| 2025-10-10 | Organon Llc | $14 | Food and Beverage | In-kind items and services | VTAMA Drug, Dermatology | 2025 | |
| 2025-10-10 | Organon Llc | $13 | Food and Beverage | In-kind items and services | VTAMA Drug, Dermatology | 2025 | |
| 2025-10-10 | Organon Llc | $12 | Food and Beverage | In-kind items and services | VTAMA Drug, Dermatology | 2025 | |
| 2025-10-09 | Organon Llc | $413 | Travel and Lodging | In-kind items and services | VTAMA Drug, Dermatology | 2025 | |
| 2025-10-09 | Organon Llc | $383 | Travel and Lodging | In-kind items and services | VTAMA Drug, Dermatology | 2025 | |
| 2025-10-09 | Organon Llc | $193 | Travel and Lodging | In-kind items and services | VTAMA Drug, Dermatology | 2025 | |
| 2025-10-09 | Arcutis Biotherapeutics, Inc. | $8 | Food and Beverage | In-kind items and services | Zoryve Drug, Dermatology | 2025 | |
| 2025-10-08 | PFIZER INC. | $25 | Food and Beverage | In-kind items and services | CIBINQO Drug, Inflammation & Immunology | 2025 | |
| 2025-10-07 | GENZYME CORPORATION | $28 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-10-07 | MAYNE PHARMA COMMERCIAL LLC | $0 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-10-06 | MAYNE PHARMA COMMERCIAL LLC | $7 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-10-02 | Galderma Laboratories, L.P. | $23 | Food and Beverage | In-kind items and services | NEMLUVIO Drug, DERMATITIS | 2025 | |
| 2025-09-30 | Regeneron Healthcare Solutions, Inc. | $5,551 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-09-30 | Regeneron Healthcare Solutions, Inc. | $47 | Travel and Lodging | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-09-30 | Organon Llc | $12 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-09-30 | MAYNE PHARMA COMMERCIAL LLC | $0 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-09-29 | Regeneron Healthcare Solutions, Inc. | $21 | Food and Beverage | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-09-29 | MAYNE PHARMA COMMERCIAL LLC | $6 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-09-26 | Regeneron Healthcare Solutions, Inc. | $119 | Food and Beverage | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-09-24 | GENZYME CORPORATION | $23 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-09-24 | ABBVIE INC. | $20 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-09-24 | MAYNE PHARMA COMMERCIAL LLC | $1 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-09-23 | Regeneron Healthcare Solutions, Inc. | $5,551 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-09-23 | Regeneron Healthcare Solutions, Inc. | $104 | Travel and Lodging | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-09-23 | Regeneron Healthcare Solutions, Inc. | $21 | Food and Beverage | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-09-23 | Incyte Corporation | $17 | Food and Beverage | Cash or cash equivalent | OPZELURA Drug, Dermatology | 2025 | |
| 2025-09-23 | Regeneron Healthcare Solutions, Inc. | $5 | Travel and Lodging | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-09-22 | MAYNE PHARMA COMMERCIAL LLC | $6 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-09-20 | Regeneron Healthcare Solutions, Inc. | $35 | Food and Beverage | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-09-17 | ABBVIE INC. | $150 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-09-17 | LNHC, Inc | $16 | Food and Beverage | In-kind items and services | ZELSUVMI Drug, DERMATOLOGY | 2025 | |
| 2025-09-16 | Ortho Dermatologics, a division of Bausch Health US, LLC | $23 | Food and Beverage | In-kind items and services | Cabtreo Drug, Dermatology | 2025 | |
| 2025-09-16 | PFIZER INC. | $18 | Food and Beverage | In-kind items and services | CIBINQO Drug, Inflammation & Immunology | 2025 | |
| 2025-09-16 | Ortho Dermatologics, a division of Bausch Health US, LLC | $2 | Food and Beverage | In-kind items and services | Cabtreo Drug, Dermatology | 2025 | |
| 2025-09-15 | Incyte Corporation | $26 | Food and Beverage | Cash or cash equivalent | OPZELURA Drug, Dermatology | 2025 | |
| 2025-09-08 | Incyte Corporation | $800 | Travel and Lodging | Cash or cash equivalent | Opzelura Drug, Dermatology | 2025 | |
| 2025-09-08 | Incyte Corporation | $339 | Travel and Lodging | Cash or cash equivalent | Opzelura Drug, Dermatology | 2025 | |
| 2025-09-08 | Incyte Corporation | $160 | Travel and Lodging | Cash or cash equivalent | Opzelura Drug, Dermatology | 2025 | |
| 2025-09-08 | Incyte Corporation | $31 | Food and Beverage | Cash or cash equivalent | OPZELURA Drug, Dermatology | 2025 | |
| 2025-09-03 | Arcutis Biotherapeutics, Inc. | $16 | Food and Beverage | In-kind items and services | Zoryve Drug, Dermatology | 2025 | |
| 2025-09-02 | Regeneron Healthcare Solutions, Inc. | $35 | Food and Beverage | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-08-28 | Incyte Corporation | $18 | Food and Beverage | Cash or cash equivalent | OPZELURA Drug, Dermatology | 2025 | |
| 2025-08-28 | Galderma Laboratories, L.P. | $5 | Food and Beverage | In-kind items and services | NEMLUVIO Drug, DERMATITIS | 2025 | |
| 2025-08-27 | GENZYME CORPORATION | $28 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-08-26 | Regeneron Healthcare Solutions, Inc. | $7,259 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-08-26 | GENZYME CORPORATION | $2,989 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | DUPIXENT Biological, Immunology | 2025 | |
| 2025-08-26 | MAYNE PHARMA COMMERCIAL LLC | $1 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-08-25 | MAYNE PHARMA COMMERCIAL LLC | $7 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-08-23 | Janssen Biotech, Inc. | $1,750 | Consulting Fee | Cash or cash equivalent | TREMFYA Drug, Immunology | 2025 | |
| 2025-08-23 | Regeneron Healthcare Solutions, Inc. | $36 | Food and Beverage | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-08-21 | GENZYME CORPORATION | $2,989 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | DUPIXENT Biological, Immunology | 2025 | |
| 2025-08-21 | Janssen Biotech, Inc. | $96 | Travel and Lodging | Cash or cash equivalent | TREMFYA Drug, Immunology | 2025 | |
| 2025-08-20 | GENZYME CORPORATION | $26 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-08-19 | LNHC, Inc | $15 | Food and Beverage | In-kind items and services | ZELSUVMI Drug, DERMATOLOGY | 2025 | |
| 2025-08-18 | Arcutis Biotherapeutics, Inc. | $2,250 | Consulting Fee | Cash or cash equivalent | Zoryve Drug, Dermatology | 2025 | |
| 2025-08-18 | Arcutis Biotherapeutics, Inc. | $348 | Travel and Lodging | Cash or cash equivalent | Zoryve Drug, Dermatology | 2025 | |
| 2025-08-14 | Galderma Laboratories, L.P. | $10 | Food and Beverage | In-kind items and services | NEMLUVIO Drug, DERMATITIS | 2025 | |
| 2025-08-14 | Arcutis Biotherapeutics, Inc. | $7 | Food and Beverage | In-kind items and services | Zoryve Drug, Dermatology | 2025 | |
| 2025-08-13 | Lilly USA, LLC | $24 | Food and Beverage | In-kind items and services | TALTZ Drug, Immunology | 2025 | |
| 2025-08-13 | MAYNE PHARMA COMMERCIAL LLC | $1 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-08-12 | Janssen Biotech, Inc. | $139 | Food and Beverage | In-kind items and services | TREMFYA Drug, Immunology | 2025 | |
| 2025-08-12 | Krystal Biotech Inc | $15 | Food and Beverage | In-kind items and services | VYJUVEK Drug, DERMATOLOGY | 2025 | |
| 2025-08-11 | Organon Llc | $14 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-08-11 | MAYNE PHARMA COMMERCIAL LLC | $7 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-08-07 | Incyte Corporation | $3,375 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-08-07 | Arcutis Biotherapeutics, Inc. | $21 | Food and Beverage | In-kind items and services | Zoryve Drug, Dermatology | 2025 | |
| 2025-08-06 | PFIZER INC. | $3,425 | Consulting Fee | Cash or cash equivalent | CIBINQO Drug, Inflammation & Immunology | 2025 | |
| 2025-08-06 | Incyte Corporation | $29 | Food and Beverage | Cash or cash equivalent | OPZELURA Drug, Dermatology | 2025 | |
| 2025-08-06 | Incyte Corporation | $10 | Food and Beverage | Cash or cash equivalent | OPZELURA Drug, Dermatology | 2025 | |
| 2025-08-05 | Regeneron Healthcare Solutions, Inc. | $32 | Food and Beverage | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-08-04 | Organon Llc | $17 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-08-04 | MAYNE PHARMA COMMERCIAL LLC | $7 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-08-04 | MAYNE PHARMA COMMERCIAL LLC | $0 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-07-31 | Almirall LLC | $19 | Food and Beverage | In-kind items and services | Klisyri Drug, Dermatology | 2025 | |
| 2025-07-31 | Galderma Laboratories, L.P. | $12 | Food and Beverage | In-kind items and services | NEMLUVIO Drug, DERMATITIS | 2025 | |
| 2025-07-29 | Incyte Corporation | $20 | Food and Beverage | Cash or cash equivalent | OPZELURA Drug, Dermatology | 2025 | |
| 2025-07-29 | ABBVIE INC. | $1 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-07-25 | GENZYME CORPORATION | $6,384 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | DUPIXENT Biological, Immunology | 2025 | |
| 2025-07-25 | Regeneron Healthcare Solutions, Inc. | $1,495 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-07-23 | Incyte Corporation | $77 | Food and Beverage | Cash or cash equivalent | 2025 | ||
| 2025-07-23 | Arcutis Biotherapeutics, Inc. | $75 | Food and Beverage | In-kind items and services | Zoryve Drug, Dermatology | 2025 | |
| 2025-07-23 | PFIZER INC. | $62 | Food and Beverage | In-kind items and services | CIBINQO Drug, Inflammation & Immunology | 2025 | |
| 2025-07-23 | Incyte Corporation | $23 | Food and Beverage | Cash or cash equivalent | 2025 | ||
| 2025-07-22 | Regeneron Healthcare Solutions, Inc. | $24 | Food and Beverage | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-07-22 | Cipher Pharmaceuticals US LLC | $18 | Food and Beverage (2 payments) | Cash or cash equivalent | Natroba Drug, Antiparasitic | 2025 | |
| 2025-07-22 | PFIZER INC. | $7 | Food and Beverage | In-kind items and services | CIBINQO Drug, Inflammation & Immunology | 2025 | |
| 2025-07-21 | PFIZER INC. | $15 | Food and Beverage | In-kind items and services | CIBINQO Drug, Inflammation & Immunology | 2025 | |
| 2025-07-21 | MAYNE PHARMA COMMERCIAL LLC | $7 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-07-21 | MAYNE PHARMA COMMERCIAL LLC | $1 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-07-17 | PFIZER INC. | $22 | Food and Beverage | In-kind items and services | CIBINQO Drug, Inflammation & Immunology | 2025 | |
| 2025-07-17 | Ortho Dermatologics, a division of Bausch Health US, LLC | $19 | Food and Beverage | In-kind items and services | Cabtreo Drug, Dermatology | 2025 | |
| 2025-07-17 | Ortho Dermatologics, a division of Bausch Health US, LLC | $8 | Food and Beverage | In-kind items and services | Cabtreo Drug, Dermatology | 2025 | |
| 2025-07-17 | Galderma Laboratories, L.P. | $6 | Food and Beverage | In-kind items and services | NEMLUVIO Drug, DERMATITIS | 2025 | |
| 2025-07-16 | LNHC, Inc | $18 | Food and Beverage | In-kind items and services | ZELSUVMI Drug, DERMATOLOGY | 2025 | |
| 2025-07-15 | MAYNE PHARMA COMMERCIAL LLC | $1 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-07-14 | GENZYME CORPORATION | $27 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-07-14 | MAYNE PHARMA COMMERCIAL LLC | $7 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-07-14 | Ortho Dermatologics, a division of Bausch Health US, LLC | $7 | Food and Beverage | In-kind items and services | Cabtreo Drug, Dermatology | 2025 | |
| 2025-07-11 | Galderma Laboratories, L.P. | $6 | Food and Beverage | In-kind items and services | NEMLUVIO Drug, DERMATITIS | 2025 | |
| 2025-07-10 | GENZYME CORPORATION | $132 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-07-10 | Regeneron Healthcare Solutions, Inc. | $21 | Food and Beverage | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-07-09 | Arcutis Biotherapeutics, Inc. | $15 | Food and Beverage | In-kind items and services | Zoryve Drug, Dermatology | 2025 | |
| 2025-07-03 | Arcutis Biotherapeutics, Inc. | $8 | Food and Beverage | In-kind items and services | Zoryve Drug, Dermatology | 2025 | |
| 2025-06-30 | PFIZER INC. | $21 | Food and Beverage | In-kind items and services | CIBINQO Drug, Inflammation & Immunology | 2025 | |
| 2025-06-30 | Ortho Dermatologics, a division of Bausch Health US, LLC | $9 | Food and Beverage | In-kind items and services | Cabtreo Drug, Dermatology | 2025 | |
| 2025-06-30 | Ortho Dermatologics, a division of Bausch Health US, LLC | $1 | Food and Beverage | In-kind items and services | Cabtreo Drug, Dermatology | 2025 | |
| 2025-06-30 | Ortho Dermatologics, a division of Bausch Health US, LLC | $1 | Food and Beverage | In-kind items and services | Cabtreo Drug, Dermatology | 2025 | |
| 2025-06-27 | Regeneron Healthcare Solutions, Inc. | $3,843 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-06-27 | Regeneron Healthcare Solutions, Inc. | $42 | Travel and Lodging | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-06-27 | Regeneron Healthcare Solutions, Inc. | $18 | Travel and Lodging | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-06-26 | Galderma Laboratories, L.P. | $8 | Food and Beverage | In-kind items and services | NEMLUVIO Drug, DERMATITIS | 2025 | |
| 2025-06-24 | Incyte Corporation | $24 | Food and Beverage | Cash or cash equivalent | OPZELURA Drug, Dermatology | 2025 | |
| 2025-06-24 | MAYNE PHARMA COMMERCIAL LLC | $0 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-06-23 | GENZYME CORPORATION | $24 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-06-23 | MAYNE PHARMA COMMERCIAL LLC | $6 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-06-19 | Regeneron Healthcare Solutions, Inc. | $26 | Food and Beverage | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-06-18 | ABBVIE INC. | $28 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-06-18 | Incyte Corporation | $4 | Food and Beverage | Cash or cash equivalent | OPZELURA Drug, Dermatology | 2025 | |
| 2025-06-16 | GENZYME CORPORATION | $4,697 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | DUPIXENT Biological, Immunology | 2025 | |
| 2025-06-16 | GENZYME CORPORATION | $13 | Travel and Lodging | Cash or cash equivalent | DUPIXENT Biological, Immunology | 2025 | |
| 2025-06-16 | Galderma Laboratories, L.P. | $5 | Food and Beverage | In-kind items and services | NEMLUVIO Drug, DERMATITIS | 2025 | |
| 2025-06-12 | Arcutis Biotherapeutics, Inc. | $16 | Food and Beverage | In-kind items and services | Zoryve Drug, Dermatology | 2025 | |
| 2025-06-11 | PFIZER INC. | $29 | Food and Beverage | In-kind items and services | CIBINQO Drug, Inflammation & Immunology | 2025 | |
| 2025-06-10 | Regeneron Healthcare Solutions, Inc. | $5,551 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-06-10 | MAYNE PHARMA COMMERCIAL LLC | $0 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-06-09 | MAYNE PHARMA COMMERCIAL LLC | $7 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-06-06 | Regeneron Healthcare Solutions, Inc. | $124 | Food and Beverage | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-06-06 | Galderma Laboratories, L.P. | $8 | Food and Beverage | In-kind items and services | NEMLUVIO Drug, DERMATITIS | 2025 | |
| 2025-06-05 | GENZYME CORPORATION | $7,259 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | DUPIXENT Biological, Immunology | 2025 | |
| 2025-06-05 | GENZYME CORPORATION | $4,697 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | DUPIXENT Biological, Immunology | 2025 | |
| 2025-06-05 | GENZYME CORPORATION | $236 | Travel and Lodging | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-06-05 | GENZYME CORPORATION | $54 | Travel and Lodging | Cash or cash equivalent | DUPIXENT Biological, Immunology | 2025 | |
| 2025-06-05 | GENZYME CORPORATION | $32 | Travel and Lodging | Cash or cash equivalent | DUPIXENT Biological, Immunology | 2025 | |
| 2025-06-05 | GENZYME CORPORATION | $26 | Food and Beverage | Cash or cash equivalent | DUPIXENT Biological, Immunology | 2025 | |
| 2025-06-05 | Galderma Laboratories, L.P. | $24 | Food and Beverage | In-kind items and services | NEMLUVIO Drug, DERMATITIS | 2025 | |
| 2025-06-05 | GENZYME CORPORATION | $20 | Food and Beverage | Cash or cash equivalent | DUPIXENT Biological, Immunology | 2025 | |
| 2025-06-04 | Regeneron Healthcare Solutions, Inc. | $32 | Food and Beverage | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-06-04 | PFIZER INC. | $24 | Food and Beverage | In-kind items and services | CIBINQO Drug, Inflammation & Immunology | 2025 | |
| 2025-06-03 | MAYNE PHARMA COMMERCIAL LLC | $1 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-06-02 | Incyte Corporation | $26 | Food and Beverage | Cash or cash equivalent | OPZELURA Drug, Dermatology | 2025 | |
| 2025-06-02 | MAYNE PHARMA COMMERCIAL LLC | $8 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-05-29 | Galderma Laboratories, L.P. | $141 | Food and Beverage | In-kind items and services | NEMLUVIO Drug, DERMATITIS | 2025 | |
| 2025-05-29 | GENZYME CORPORATION | $26 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-05-22 | Arcutis Biotherapeutics, Inc. | $8 | Food and Beverage | In-kind items and services | Zoryve Drug, Dermatology | 2025 | |
| 2025-05-22 | PFIZER INC. | $4 | Food and Beverage | In-kind items and services | CIBINQO Drug, Inflammation & Immunology | 2025 |
The latest 200 records of 1,395.
Research payments naming this person as principal investigator
| Date | Company | Paid to | Amount | Study | Year |
|---|---|---|---|---|---|
| 2025-12-19 | Incyte Corporation | STAT MEDICAL SERVICES | $4,469 | A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo | 2025 |
| 2025-11-06 | Ferring Pharmaceuticals AS | Yale University | $3,550 | A Phase 2, Randomised, Multi-center, Open Label Trial to Evaluate the Safety and Efficacy of Intravesical Nadofaragene F | 2025 |
| 2025-10-29 | Incyte Corporation | STAT MEDICAL SERVICES | $1,933 | A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo | 2025 |
| 2025-10-23 | Ferring Pharmaceuticals AS | Yale University | $10,581 | A Phase 2, Randomised, Multi-center, Open Label Trial to Evaluate the Safety and Efficacy of Intravesical Nadofaragene F | 2025 |
| 2025-09-23 | Incyte Corporation | STAT MEDICAL SERVICES | $2,504 | A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo | 2025 |
| 2025-09-04 | Ferring Pharmaceuticals AS | Yale University | $1,200 | A Phase 2, Randomised, Multi-center, Open Label Trial to Evaluate the Safety and Efficacy of Intravesical Nadofaragene F | 2025 |
| 2025-09-04 | Ferring Pharmaceuticals AS | Yale University | $1,800 | A Phase 2, Randomised, Multi-center, Open Label Trial to Evaluate the Safety and Efficacy of Intravesical Nadofaragene F | 2025 |
| 2025-08-26 | Incyte Corporation | STAT MEDICAL SERVICES | $5,024 | A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo | 2025 |
| 2025-08-14 | Incyte Corporation | STAT MEDICAL SERVICES | $2,259 | A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo | 2025 |
| 2025-08-04 | Ferring Pharmaceuticals AS | Yale University | $5,900 | A Phase 2, Randomised, Multi-center, Open Label Trial to Evaluate the Safety and Efficacy of Intravesical Nadofaragene F | 2025 |
| 2025-07-25 | Ferring Pharmaceuticals AS | Yale University | $1,450 | A Phase 2, Randomised, Multi-center, Open Label Trial to Evaluate the Safety and Efficacy of Intravesical Nadofaragene F | 2025 |
| 2025-06-24 | Incyte Corporation | STAT MEDICAL SERVICES | $7,331 | A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo | 2025 |
| 2025-06-05 | Ferring Pharmaceuticals AS | Yale University | $30,000 | A Phase 2, Randomised, Multi-center, Open Label Trial to Evaluate the Safety and Efficacy of Intravesical Nadofaragene F | 2025 |
| 2025-02-05 | Eli Lilly and Company | SUNRISE MEDICAL RESEARCH INC | $21,074 | A PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS (PK | 2025 |
| 2025-01-29 | Incyte Corporation | ACRC TRIALS | $12,000 | A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo | 2025 |
| 2024-12-18 | Arcutis Biotherapeutics, Inc. | Marwah Investments Corporation dba ACRC Trials | $1,000 | A Phase 3, Multicenter, Open-Label Extension Study of the Long-Term Safety of ARQ-151 Cream 0.15% and ARQ-151 Cream 0.05 | 2024 |
| 2024-12-18 | Arcutis Biotherapeutics, Inc. | Marwah Investments Corporation dba ACRC Trials | $385 | A Phase 3, Multicenter, Open-Label Extension Study of the Long-Term Safety of ARQ-151 Cream 0.15% and ARQ-151 Cream 0.05 | 2024 |
| 2024-12-02 | Arcutis Biotherapeutics, Inc. | Marwah Investments Corporation dba ACRC Trials | $1,968 | A Phase 3, Multicenter, Open-Label Extension Study of the Long-Term Safety of ARQ-151 Cream 0.15% and ARQ-151 Cream 0.05 | 2024 |
| 2024-12-02 | Arcutis Biotherapeutics, Inc. | Marwah Investments Corporation dba ACRC Trials | $3,000 | A Phase 3, Multicenter, Open-Label Extension Study of the Long-Term Safety of ARQ-151 Cream 0.15% and ARQ-151 Cream 0.05 | 2024 |
| 2024-08-03 | Dermavant Sciences, Inc. | Marwah Investments Corporation dba ACRC Trials | $73 | AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOP | 2024 |
| 2024-08-03 | Dermavant Sciences, Inc. | Marwah Investments Corporation dba ACRC Trials | $59 | AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOP | 2024 |
| 2024-08-03 | Dermavant Sciences, Inc. | Marwah Investments Corporation dba ACRC Trials | $73 | AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOP | 2024 |
| 2024-08-03 | Dermavant Sciences, Inc. | Marwah Investments Corporation dba ACRC Trials | $59 | AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOP | 2024 |
| 2024-08-03 | Dermavant Sciences, Inc. | Marwah Investments Corporation dba ACRC Trials | $59 | AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOP | 2024 |
| 2024-08-03 | Dermavant Sciences, Inc. | Marwah Investments Corporation dba ACRC Trials | $73 | AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOP | 2024 |
| 2024-08-03 | Dermavant Sciences, Inc. | Marwah Investments Corporation dba ACRC Trials | $57 | AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOP | 2024 |
| 2024-08-03 | Dermavant Sciences, Inc. | Marwah Investments Corporation dba ACRC Trials | $25 | AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOP | 2024 |
| 2024-08-03 | Dermavant Sciences, Inc. | Marwah Investments Corporation dba ACRC Trials | $59 | AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOP | 2024 |
| 2024-08-03 | Dermavant Sciences, Inc. | Marwah Investments Corporation dba ACRC Trials | $73 | AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOP | 2024 |
| 2024-08-03 | Dermavant Sciences, Inc. | Marwah Investments Corporation dba ACRC Trials | $59 | AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOP | 2024 |
| 2024-08-03 | Dermavant Sciences, Inc. | Marwah Investments Corporation dba ACRC Trials | $73 | AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOP | 2024 |
| 2024-08-03 | Dermavant Sciences, Inc. | Marwah Investments Corporation dba ACRC Trials | $59 | AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOP | 2024 |
| 2024-08-03 | Dermavant Sciences, Inc. | Marwah Investments Corporation dba ACRC Trials | $59 | AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOP | 2024 |
| 2024-08-03 | Dermavant Sciences, Inc. | Marwah Investments Corporation dba ACRC Trials | $73 | AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOP | 2024 |
| 2024-08-03 | Dermavant Sciences, Inc. | Marwah Investments Corporation dba ACRC Trials | $57 | AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOP | 2024 |
| 2024-08-03 | Dermavant Sciences, Inc. | Marwah Investments Corporation dba ACRC Trials | $25 | AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOP | 2024 |
| 2024-08-03 | Dermavant Sciences, Inc. | Marwah Investments Corporation dba ACRC Trials | $59 | AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOP | 2024 |
| 2024-07-23 | Dermavant Sciences, Inc. | Marwah Investments Corporation dba ACRC Trials | $2,000 | AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOP | 2024 |
| 2024-07-23 | Dermavant Sciences, Inc. | Marwah Investments Corporation dba ACRC Trials | $63 | AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOP | 2024 |
| 2024-07-23 | Dermavant Sciences, Inc. | Marwah Investments Corporation dba ACRC Trials | $73 | AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOP | 2024 |
| 2024-07-23 | Dermavant Sciences, Inc. | Marwah Investments Corporation dba ACRC Trials | $59 | AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOP | 2024 |
| 2024-07-23 | Dermavant Sciences, Inc. | Marwah Investments Corporation dba ACRC Trials | $59 | AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOP | 2024 |
| 2024-07-23 | Dermavant Sciences, Inc. | Marwah Investments Corporation dba ACRC Trials | $1,000 | AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOP | 2024 |
| 2024-07-23 | Dermavant Sciences, Inc. | Marwah Investments Corporation dba ACRC Trials | $1,358 | AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOP | 2024 |
| 2024-07-01 | SANOFI US SERVICES INC. | Marwah Investments Cort | $364 | Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) | 2024 |
| 2024-02-05 | Arcutis Biotherapeutics, Inc. | Marwah Investments Corporation dba ACRC Trials | $357 | A Phase 3, Multicenter, Open-Label Extension Study of the Long-Term Safety of ARQ-151 Cream 0.15% and ARQ-151 Cream 0.05 | 2024 |
| 2024-01-17 | Dermavant Sciences, Inc. | Marwah Investments Corporation dba ACRC Trials | $1,201 | AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOP | 2024 |
| 2024-01-17 | Dermavant Sciences, Inc. | Marwah Investments Corporation dba ACRC Trials | $1,400 | AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOP | 2024 |
| 2024-01-09 | Eli Lilly and Company | SUNRISE MEDICAL RESEARCH INC | $15,445 | A PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS (PK | 2024 |
| 2023-12-04 | Arcutis Biotherapeutics, Inc. | Marwah Investments Corporation dba ACRC Trials | $3,000 | A Phase 3, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0. | 2023 |
| 2023-12-04 | Arcutis Biotherapeutics, Inc. | Marwah Investments Corporation dba ACRC Trials | $1,910 | A Phase 3, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0. | 2023 |
| 2023-12-04 | Arcutis Biotherapeutics, Inc. | Marwah Investments Corporation dba ACRC Trials | $1,729 | A Phase 3, Multicenter, Open-Label Extension Study of the Long-Term Safety of ARQ-151 Cream 0.15% and ARQ-151 Cream 0.05 | 2023 |
| 2023-12-01 | SANOFI US SERVICES INC. | Marwah Investments Cort | $2,000 | Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) | 2023 |
| 2023-12-01 | SANOFI US SERVICES INC. | Marwah Investments Cort | $780 | Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) | 2023 |
| 2023-11-30 | Dermavant Sciences, Inc. | Marwah Investments Corporation dba ACRC Trials | $1,125 | AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOP | 2023 |
| 2023-11-30 | Dermavant Sciences, Inc. | Marwah Investments Corporation dba ACRC Trials | $1,125 | AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOP | 2023 |
| 2023-11-06 | Arcutis Biotherapeutics, Inc. | Marwah Investments Corporation dba ACRC Trials | $357 | A Phase 3, Multicenter, Open-Label Extension Study of the Long-Term Safety of ARQ-151 Cream 0.15% and ARQ-151 Cream 0.05 | 2023 |
| 2023-10-16 | Arcutis Biotherapeutics, Inc. | Marwah Investments Corporation dba ACRC Trials | $385 | A Phase 3, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0. | 2023 |
| 2023-10-16 | Arcutis Biotherapeutics, Inc. | Marwah Investments Corporation dba ACRC Trials | $100 | A Phase 3, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0. | 2023 |
| 2023-10-16 | Arcutis Biotherapeutics, Inc. | Marwah Investments Corporation dba ACRC Trials | $2,800 | A Phase 3, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0. | 2023 |
| 2023-10-11 | Dermavant Sciences, Inc. | Marwah Investments Corporation dba ACRC Trials | $1,125 | AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOP | 2023 |
| 2023-10-11 | Dermavant Sciences, Inc. | Marwah Investments Corporation dba ACRC Trials | $1,400 | AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOP | 2023 |
| 2023-10-06 | Eli Lilly and Company | SUNRISE MEDICAL RESEARCH INC | $12,963 | A PHASE 3 DOUBLE-BLIND RANDOMIZED PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY SAFETY AND PHARMACOKINETICS (PK) OF | 2023 |
| 2023-10-04 | Arcutis Biotherapeutics, Inc. | Marwah Investments Corporation dba ACRC Trials | $186 | A Phase 3, Multicenter, Open-Label Extension Study of the Long-Term Safety of ARQ-151 Cream 0.15% and ARQ-151 Cream 0.05 | 2023 |
| 2023-09-13 | Dermavant Sciences, Inc. | Marwah Investments Corporation dba ACRC Trials | $72 | A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN W | 2023 |
| 2023-09-13 | Dermavant Sciences, Inc. | Marwah Investments Corporation dba ACRC Trials | $19 | A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN W | 2023 |
| 2023-09-13 | Dermavant Sciences, Inc. | Marwah Investments Corporation dba ACRC Trials | $19 | A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN W | 2023 |
| 2023-09-13 | Dermavant Sciences, Inc. | Marwah Investments Corporation dba ACRC Trials | $80 | A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN W | 2023 |
| 2023-09-13 | Dermavant Sciences, Inc. | Marwah Investments Corporation dba ACRC Trials | $80 | A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN W | 2023 |
| 2023-09-13 | Dermavant Sciences, Inc. | Marwah Investments Corporation dba ACRC Trials | $72 | A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN W | 2023 |
| 2023-09-13 | Dermavant Sciences, Inc. | Marwah Investments Corporation dba ACRC Trials | $59 | A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN W | 2023 |
| 2023-09-13 | Dermavant Sciences, Inc. | Marwah Investments Corporation dba ACRC Trials | $59 | A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN W | 2023 |
| 2023-09-13 | Dermavant Sciences, Inc. | Marwah Investments Corporation dba ACRC Trials | $73 | A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN W | 2023 |
| 2023-09-13 | Dermavant Sciences, Inc. | Marwah Investments Corporation dba ACRC Trials | $73 | A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN W | 2023 |
| 2023-09-05 | Arcutis Biotherapeutics, Inc. | Marwah Investments Corporation dba ACRC Trials | $2,079 | A Phase 3, Multicenter, Open-Label Extension Study of the Long-Term Safety of ARQ-151 Cream 0.15% and ARQ-151 Cream 0.05 | 2023 |
| 2023-08-26 | Dermavant Sciences, Inc. | Marwah Investments Corporation dba ACRC Trials | $1,400 | AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOP | 2023 |
| 2023-08-10 | Eli Lilly and Company | Marwah Investments Corporation | $13,380 | A PHASE 3 DOUBLE-BLIND RANDOMIZED PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY SAFETY AND PHARMACOKINETICS (PK) OF | 2023 |
| 2023-06-26 | Arcutis Biotherapeutics, Inc. | Marwah Investments Corporation dba ACRC Trials | $4,096 | A Phase 3, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0. | 2023 |
| 2023-06-13 | Dermavant Sciences, Inc. | Marwah Investments Corporation dba ACRC Trials | $1,125 | AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOP | 2023 |
| 2023-05-29 | Arcutis Biotherapeutics, Inc. | Marwah Investments Corporation dba ACRC Trials | $1,543 | A Phase 3, Multicenter, Open-Label Extension Study of the Long-Term Safety of ARQ-151 Cream 0.15% and ARQ-151 Cream 0.05 | 2023 |
| 2023-05-23 | Arcutis Biotherapeutics, Inc. | Marwah Investments Corporation dba ACRC Trials | $75 | A Phase 3, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0 | 2023 |
| 2023-05-20 | Dermavant Sciences, Inc. | Marwah Investments Corporation dba ACRC Trials | $1,400 | AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOP | 2023 |
| 2023-05-16 | Arcutis Biotherapeutics, Inc. | Marwah Investments Corporation dba ACRC Trials | $1,650 | A Phase 3, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0 | 2023 |
| 2023-05-01 | Arcutis Biotherapeutics, Inc. | Marwah Investments Corporation dba ACRC Trials | $3,894 | A Phase 3, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0 | 2023 |
| 2023-05-01 | Arcutis Biotherapeutics, Inc. | Marwah Investments Corporation dba ACRC Trials | $1,915 | A Phase 3, Multicenter, Open-Label Extension Study of the Long-Term Safety of ARQ-151 Cream 0.15% and ARQ-151 Cream 0.05 | 2023 |
| 2023-04-20 | Arcutis Biotherapeutics, Inc. | Marwah Investments Corporation dba ACRC Trials | $200 | A Phase 3, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0 | 2023 |
| 2023-04-20 | Arcutis Biotherapeutics, Inc. | Marwah Investments Corporation dba ACRC Trials | $1,000 | A Phase 3, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0 | 2023 |
| 2023-04-20 | Arcutis Biotherapeutics, Inc. | Marwah Investments Corporation dba ACRC Trials | $3,150 | A Phase 3, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0 | 2023 |
| 2023-04-20 | Arcutis Biotherapeutics, Inc. | Marwah Investments Corporation dba ACRC Trials | $1,540 | A Phase 3, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0 | 2023 |
| 2023-04-14 | Dermavant Sciences, Inc. | Marwah Investments Corporation dba ACRC Trials | $488 | AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOP | 2023 |
| 2023-04-14 | Dermavant Sciences, Inc. | Marwah Investments Corporation dba ACRC Trials | $1,125 | AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOP | 2023 |
| 2023-04-14 | Dermavant Sciences, Inc. | Marwah Investments Corporation dba ACRC Trials | $1,125 | AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOP | 2023 |
| 2023-04-04 | SANOFI US SERVICES INC. | Marwah Investments Cort | $364 | Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) | 2023 |
| 2023-04-03 | Arcutis Biotherapeutics, Inc. | Marwah Investments Corporation dba ACRC Trials | $1,850 | A Phase 3, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0. | 2023 |
| 2023-04-03 | Arcutis Biotherapeutics, Inc. | Marwah Investments Corporation dba ACRC Trials | $814 | A Phase 3, Multicenter, Open-Label Extension Study of the Long-Term Safety of ARQ-151 Cream 0.15% and ARQ-151 Cream 0.05 | 2023 |
| 2023-04-03 | Arcutis Biotherapeutics, Inc. | Marwah Investments Corporation dba ACRC Trials | $3,000 | A Phase 3, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0 | 2023 |
| 2023-04-03 | Arcutis Biotherapeutics, Inc. | Marwah Investments Corporation dba ACRC Trials | $3,000 | A Phase 3, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0 | 2023 |
| 2023-02-27 | Arcutis Biotherapeutics, Inc. | Marwah Investments Corporation dba ACRC Trials | $1,810 | A Phase 3, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0. | 2023 |
| 2023-02-27 | Arcutis Biotherapeutics, Inc. | Marwah Investments Corporation dba ACRC Trials | $7,495 | A Phase 3, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0. | 2023 |
| 2023-02-17 | Dermavant Sciences, Inc. | Marwah Investments Corporation dba ACRC Trials | $1,086 | AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOP | 2023 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Grapevine, TX, county Tarrant County, TX, state Texas; placed by its city name.
| Measure | Place (city or town) Grapevine, TX | County Tarrant County, TX | State Texas |
|---|---|---|---|
| Population B01003 | 51,139 | 2,167,390 | 30,188,424 |
| Population, 2020 census P1 | 50,631 | 2,110,640 | 29,145,505 |
| Median age B01002 | 39.7 | 35.2 | 35.6 |
| Under 18 B01001 | 21.3% | 25.4% | 25.0% |
| 65 and over B01001 | 14.1% | 12.3% | 13.4% |
| Households B11001 | 21,593 | 782,419 | 10,992,816 |
| Foreign born B05002 | 17.2% | 17.2% | 17.6% |
| Median household income B19013 | $111,376 | $84,207 | $78,476 |
| Median family income B19113 | $148,036 | $102,307 | $94,599 |
| Per capita income B19301 | $61,797 | $42,755 | $40,752 |
| Poverty rate B17001 | 6.7% | 11.1% | 13.8% |
| Unemployment rate B23025 | 4.7% | 4.7% | 5.3% |
| Civilian labor force B23025 | 30,643 | 1,156,004 | 15,233,563 |
| Mean commute (minutes) B08013 | 22.3 | 26.8 | 26.7 |
| Bachelor's degree or higher B15003 | 57.5% | 34.8% | 33.8% |
| Housing units B25001 | 22,885 | 843,257 | 12,128,515 |
| Owner-occupied B25003 | 52.7% | 59.3% | 62.6% |
| Renters B25003 | 47.3% | 40.7% | 37.4% |
| Median home value B25077 | $493,100 | $323,900 | $283,800 |
| Median gross rent B25064 | $1,863 | $1,547 | $1,403 |
| White, not Hispanic B03002 | 61.9% | 42.0% | 39.1% |
| Black B03002 | 4.4% | 17.3% | 11.9% |
| Hispanic or Latino B03002 | 21.0% | 30.3% | 39.7% |
| Asian B03002 | 7.9% | 6.1% | 5.5% |
| American Indian and Alaska Native B03002 | 0.2% | 0.1% | 0.1% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Grapevine, TX.
Comments